Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines demonstrates a positive financial outlook with anticipated revenue growth from the launches of zanidatamab and tarlatamab in China, alongside established products such as Xgeva and Blincyto, contributing to a strong revenue stream. The company’s flagship drug, Brukinsa, which commands significant market preference over competitor BTK inhibitors, is projected to reach peak sales of approximately $7.1 billion, further supported by robust prescription volume and seasonal sales patterns. Additionally, the emergence of next-generation therapies like sonrotoclaxis, poised to outperform existing treatments, is expected to bolster BeOne’s revenue further in the long term.

Bears say

BeOne Medicines faces a negative outlook primarily due to slower-than-expected product uptake and challenges with its pipeline programs, particularly failures in solid tumor initiatives and differentiation of other candidates that could negatively impact revenue growth. Additionally, the company's reliance on Brukinsa, which constitutes over 60% of its revenue, poses a significant risk, especially given past revenue misses and concerns about enrollment and commercialization delays. Furthermore, geopolitical risks associated with its Chinese origins, high cash burn without guaranteed marketable outcomes, and the crowded competitive landscape in hematologic oncology compound the financial uncertainties surrounding BeOne's future performance.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $374.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $374.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.